Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

B1160000

Bupivacaine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H28N2O · HCl
Número de CAS:
18010-40-7
Peso molecular:
324.89
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

bupivacaine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H

InChI key

SIEYLFHKZGLBNX-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bupivacaine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

1078507

Bupivacaine hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000088

Bupivacaine impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000089

Bupivacaine impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001575

2,6-Dimethylaniline, European Pharmacopoeia (EP) Reference Standard

1078529

Bupivacaine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1078518

Bupivacaine Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1738

Bupivacaine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1756

Bupivacaine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP479

Bupivacaine hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR9084

(S)-Bupivacaine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9147

N-(2,6-Dimethylphenyl)pyridine-2-carboxamide, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Michael R Fettiplace et al.
Anesthesiology, 120(4), 915-925 (2014-02-06)
Recent publications have questioned the validity of the "lipid sink" theory of lipid resuscitation while others have identified sink-independent effects and posed alternative mechanisms such as hemodilution. To address these issues, the authors tested the dose-dependent response to intravenous lipid
Qing-he Zhou et al.
Anesthesia and analgesia, 119(1), 203-206 (2014-05-09)
The spread of spinal anesthesia is highly unpredictable. In patients with increased abdominal girth and short stature, a greater cephalad spread after a fixed amount of subarachnoidally administered plain bupivacaine is often observed. We hypothesized that there is a strong
Ya-Hsien Huang et al.
The Journal of surgical research, 193(1), 407-414 (2014-08-16)
We sough to elucidate whether purinergic P2X7 receptor is actively involved in the effects of levobupivacaine on inhibiting microglia activation. Microglia were treated with lipopolysaccharide (LPS, 50 ng/mL), LPS plus levobupivacaine (50 μM), or LPS plus levobupivacaine plus the P2X7 receptor agonist
Mingquan Chen et al.
Anesthesia and analgesia, 118(4), 863-868 (2014-03-22)
In this study, we sought to determine the median effective dose (ED50) for motor block of intrathecally administered plain bupivacaine in adults (20-80 years) and to assess the effect of age on ED50 required for motor block. This study was
Michael J Beebe et al.
Clinical orthopaedics and related research, 472(5), 1394-1399 (2013-07-17)
Continuous femoral nerve block has been shown to decrease opioid use, improve postoperative pain scores, and decrease length of stay. However, several studies have raised the concern that continuous femoral nerve block may delay patient ambulation and increase the risk
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico